Cardlytics Sees Unusually High Options Volume (NASDAQ:CDLX)

Cardlytics, Inc. (NASDAQ:CDLX) saw some unusual options trading on Friday. Traders purchased 4,383 call options on the stock. This is an increase of approximately 255% compared to the average volume of 1,235 call options.

Wall Street Analysts Forecast Growth

Separately, Evercore ISI decreased their target price on shares of Cardlytics from $3.00 to $2.00 and set an “in-line” rating on the stock in a research report on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $2.25.

Cardlytics Trading Down 12.0%

NASDAQ CDLX opened at $2.43 on Friday. The stock has a market cap of $129.37 million, a PE ratio of -0.67 and a beta of 1.19. The company’s 50-day moving average price is $1.52 and its 200-day moving average price is $1.71. Cardlytics has a 12 month low of $0.85 and a 12 month high of $5.24. The company has a current ratio of 1.16, a quick ratio of 1.16 and a debt-to-equity ratio of 2.87.

Insider Transactions at Cardlytics

In other Cardlytics news, CEO Amit Gupta sold 68,685 shares of the company’s stock in a transaction dated Tuesday, August 19th. The shares were sold at an average price of $1.12, for a total transaction of $76,927.20. Following the completion of the sale, the chief executive officer directly owned 491,759 shares in the company, valued at $550,770.08. This represents a 12.26% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last 90 days, insiders have sold 156,265 shares of company stock worth $187,768. 4.40% of the stock is owned by insiders.

Institutional Investors Weigh In On Cardlytics

A number of institutional investors have recently added to or reduced their stakes in the stock. Northern Trust Corp lifted its holdings in Cardlytics by 8.0% in the 4th quarter. Northern Trust Corp now owns 373,770 shares of the company’s stock valued at $1,387,000 after purchasing an additional 27,536 shares in the last quarter. BNP Paribas Financial Markets raised its holdings in shares of Cardlytics by 112.2% during the 4th quarter. BNP Paribas Financial Markets now owns 41,907 shares of the company’s stock worth $155,000 after acquiring an additional 22,162 shares during the period. Millennium Management LLC purchased a new position in shares of Cardlytics during the 4th quarter worth $535,000. ProShare Advisors LLC purchased a new position in shares of Cardlytics during the 4th quarter worth $43,000. Finally, Two Sigma Investments LP raised its holdings in shares of Cardlytics by 12.5% during the 4th quarter. Two Sigma Investments LP now owns 94,901 shares of the company’s stock worth $352,000 after acquiring an additional 10,508 shares during the period. Institutional investors and hedge funds own 68.10% of the company’s stock.

About Cardlytics

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.